meta
|
evidence
oncology
Living systematic review and meta-analysis
cholangiocarcinoma
breast cancer (BC)
2
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
antibody–drug conjugate
sacituzumab govitecan
trastuzumab deruxtecan
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
aurora kinase inhibitors
alisertib plus paclitaxel
biguanide
metformin
celecoxib plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor
abemaciclib plus endocrine therapy
abemaciclib plus fulvestrant
dalpiciclib plus fulvestrant
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
palbociclib plus fulvestrant
palbociclib plus letrozole
ribociclib based treatment
ribociclib plus endocrine therapy
ribociclib plus fulvestrant
ribociclib plus letrozole
HDAC inhibitor
entinostat plus exemestane
tucidinostat based treatment
tucidinostat plus exemestane
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine
HER2 inhibitor
neratinib based treatment
neratinib
neratinib plus capecitabine
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
trastuzumab plus endocrine therapy
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
lapatinib plus capecitabine
lapatinib plus fulvestrant
lapatinib plus letrozole
lapatinib plus trastuzumab
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane
ganitumab plus endocrine therapy
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus nab-paclitaxel
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
atezolizumab plus paclitaxel
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
pembrolizumab plus SoC
Immunostimulant
vaccine
AE37 vaccine plus GM-CSF
GP2 vaccine plus GM-CSF
OBI-822/OBI-821 plus cyclophosphamide
inetetamab plus vinorelbine
mTOR inhibitors
everolimus
sapanisertib plus fulvestrant
phosphoinositide 3-kinase (PI3K) inhibitor
alpelisib based treatment
alpelisib plus fulvestrant
alpelisib plus letrozole
buparlisib based treatment
buparlisib plus fulvestrant
buparlisib plus letrozole
taselisib based treatment
taselisib plus letrozole
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
talazoparib
veliparib plus paclitaxel plus carboplatin
target therapy
margetuximab based treatment
margetuximab plus chemotherapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel
cediranib plus fulvestrant
versus all
vs antibody–drug conjugate
vs trastuzumab emtansine
vs chemotherapy
vs doxorubicin plus cyclophosphamide followed by docetaxel
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide
vs vinca alkaloids
vs vinorelbine
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
vs endocrine therapy
vs aromatase inhibitor
vs exemestane
vs exemestane plus ridaforolimus
vs fulvestrant
vs letrozole
vs GM-CSF
vs HER inhibitor
vs HER2 inhibitor
vs pertuzumab based treatment
vs pertuzumab plus trastuzumab plus cyclophosphamide
vs pertuzumab plus trastuzumab plus docetaxel
vs trastuzumab based treatment
vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
vs trastuzumab
vs trastuzumab plus capecitabine
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel
vs trastuzumab plus endocrine therapy
vs trastuzumab plus vinorelbine
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib
vs lapatinib plus capecitabine
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
VEGF(R) inhibitor
cediranib plus fulvestrant
Comparator:
vs fulvestrant;
Risk of bias:
low;
some concerns;
high;
NA;